Living with Primary Immunodeficiencies: CVID—Enteropathy from the Perspective of a Gastroenterologist

Common variable immunodeficiency (CVID), the most prevalent symptomatic primary antibody deficiency (∼1:25,000), in its symptomatic spectrum reaches way beyond intractable, chronic, and recurrent infections. Noninfectious enteropathy (CVID-E)—affecting 15–30% of patients—has emerged as a pivotal manifestation of the natural disease trajectory, with approximately 11-fold increased mortality risk. CVID-E is pathologically determined by villous atrophy, absent mucosal plasma cells, and abundant CD8+ T cell infiltration—yielding the phenotype that often mimics celiac disease. There are three pathogenic determinants that have been elucidated so far. First, almost absent mucosal IgA is permeating and facilitating gut pathogen expansion. With this process, gut membrane lipid metabolism is shifted toward inflammatory cascades, which may render an inflammatory bowel disease (IBD)-like phenotype. Second, a mixed and specific type I/III and type II interferon release drives CD8+ T cell cytotoxicity and macrophage recruitment, producing a graft-versus-host-like mucosal damage pattern yielding apparent villous injury. Third, chronic norovirus infection further augments this interferon-driven pathway, leading to high-grade epithelial damage even in early-onset disease. USIDNET registry analysis (n = 1,415) confirmed that CVID-E patients exhibit significantly lower performance status, higher rates of concomitant autoimmunity (30.7%), granulomatous disease, and even malignancy. Treatment is largely empirical with limited evidence-based data. Immunoglobulin replacement does not mitigate symptoms of enteropathy, and although corticosteroids restore architecture, they impose prohibitive infectious risk. Although TNF-α blockers and thiopurines achieved complete remission in select patient cohorts, overall therapeutic response was unsatisfying. Molecular medical tactics—employing JAK inhibitors targeting the interferon-specific pathways, namely abatacept for CTLA-4-related dysregulation—represent the most promising tool. CVID-E is a complicated disorder because it stands at the very intersection of immunodeficiency, immune dysregulation, and mucosal pathology where these determinants encompass collapsed humoral defense, gut dysbiosis, and unbalanced interferon-driven epithelial necrosis converge. Multicenter randomized controlled trials and precision therapeutics are urgently needed to supersede the current empirical interventions with a fully evidence-based approach.